BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced the issuance of a patent extending the exclusivity of the BioErodible MucoAdhesive (BEMA) drug delivery technology in Canada from 2017 to 2027. The patent was been reviewed by the Office of Patented Medicines for listing in the Canadian Patent Register and was found eligible for listing.
BEMA is BDSI's core drug delivery technology and the basis for its first commercialized product, ONSOLIS, as well as for BEMA Buprenorphine, which is currently in Phase 3 clinical development in the U.S. for the treatment of moderate to severe chronic pain. Canadian Patent No. 2,658,585 provides additional exclusivity relating to formulation characteristics for enhanced drug absorption from the BEMA drug delivery technology. This patent provides additional patent protection for ONSOLIS, BEMA Buprenorphine and BEMA Buprenorphine/Naloxone, a potential treatment for opioid dependence.
ONSOLIS has been approved by regulatory authorities in Canada and will be marketed by Meda Valeant Pharma Canada Inc., a joint venture between BDSI's commercial partner Meda, and Valeant Canada Limited.
Transcranial ultrasound stimulation: A new frontier in noninvasive brain therapy